Biovail Seeks Damages From Marion Merrell Dow

5 December 1994

- Biovail is seeking $480 million in damages from Marion Merrell Dow on antitrust grounds, alleging that MMD's patent litigation regarding once-daily diltiazem simply represents a means of delaying the approval of Hoechst-Roussel/Biovail's product. Because MMD has filed a patent infringement notice, under US law Hoechst's New Drug Application cannot be approved until 30 months after MMD's receipt of notification that an NDA for the generic product has been filed. MMD said it believed the Biovail suit was without merit.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight